| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/31/2009 | US7511049 7-carboxamido- or sulfonamido-substituted: 2-Phenyl-3-cyclopropyl-7-(4-pyridylcarboxamido)pyrazolo[1.5a]pyrimidine; anticarcinogenic, antiinflammatory, neurodegenerative agent, viricide; breast canceer, arthritis, Alzheimer's disease, cardiovascular diseases, with other active compounds |
| 03/31/2009 | US7511047 Kinase inhibitors |
| 03/31/2009 | US7511046 Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists |
| 03/31/2009 | US7511045 Dihydrothienopyrimidines; gastrointestinal disorders; cancer |
| 03/31/2009 | US7511044 Vanilloid receptor ligands and their use in treatments |
| 03/31/2009 | US7511043 farnesoid X receptor; to mitigate and thereby treat hypercholesterolemia; antagonists, which block the negative feedback downregulation of cyp7a expression produced by certain cholic acids |
| 03/31/2009 | US7511042 1-[5-(5-tert-Butyl-2-methoxy-3-methylsulfamoyl-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2,2-dimethyl-propyl)-amide; small molecule cytokine inhibitor; optimized efficacy, pharmacokinetic; antiinflammatory agent, osteoarthritis, asthma, gastrointestinal, respiratory disorder |
| 03/31/2009 | US7511041 Fused azole-pyrimidine derivatives |
| 03/31/2009 | US7511039 Thrombin inhibitors; protease inhibition, kinase inhibition, CAAX inhibition, interference with peptides binding to SH2 domains and inhibition of MCH-I and/or MHC II presentation of peptides to T cell receptors |
| 03/31/2009 | US7511038 Pyridazin-3(2H)-one derivatives and their use as PDE4 inhibitors |
| 03/31/2009 | US7511037 N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor |
| 03/31/2009 | US7511036 2-hydroxy-5,6-dimethyl-2-phenyl-2,3-dihydro-(1, 4)-thiazine-4-carbaldehyde; converted under acidic conditions to thiazolium agents that can prevent advanced glycated end products (AGEs) crosslink formation; hypotensive agent; reduced vascular compliance, diastolic dysfunction and heart failure |
| 03/31/2009 | US7511035 6-{[(2-{4-[3-fluoro-6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl)amino]methyl}-2H-pyrido[3,2-b][1,4]thiazin-3-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli |
| 03/31/2009 | US7511034 for the treatment and/or prevention of medical dysfunctions and diseases such as stroke, Parkinson's disease, and Alzheimer's disease caused by reactive oxygen species and/or excess Zn ions; neuroprotectants |
| 03/31/2009 | US7511033 Dihydro-benzo[B][1,4]diazepin-2-one sulfonamide derivatives |
| 03/31/2009 | US7511032 Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
| 03/31/2009 | US7511031 Transcutaneous photodynamic therapy; patch placed over target tissue; liposomal, transdermal, iontophoretic photosensitizing agent; light emitting diodes; atherosclerotic lesions and restenotic lesions |
| 03/31/2009 | US7511030 vitamin D receptors binder; intestinal calcium transport activity; osteoporosis or renal osteodystrophy; autoimmune diseases: multiple sclerosis, lupus, diabetes mellitus, host versus graft reaction; antiinflammatory: rheumatoid arthritis, asthma, celiac disease, ulcerative colitis and Crohn's disease |
| 03/31/2009 | US7511029 Pesticidal diazene oxide carboxylates |
| 03/31/2009 | US7511028 Stepped up dosage treatment for osteoporosis of inner ear bones; delaying surgical intervention |
| 03/31/2009 | US7511027 Administering a nucleoside or a nucleoside analog, such as (5'-fluoro-5-methyl-beta-arabinofuranosyl-uridine) or salt or prodrug that suppresses the expression of hepatitis B surface or preS1 antigen in the host 100-fold |
| 03/31/2009 | US7511026 Therapeutic agent for nerve damage |
| 03/31/2009 | US7511025 Contact tumor cell expressing matrix metalloproteinase 1 with siRNA that has a sequence complementary to part of a matrix metalloproteinase 1 nucleic acid sequence specifically inhibiting synthesis or expression; cancer |
| 03/31/2009 | US7511023 adriamycin; chemotherapy; sustained release |
| 03/31/2009 | US7511022 Substituted indole-O-glucosides |
| 03/31/2009 | US7511021 2-{3-[2-(2,3-Dihydro-benzofuran-5-yl)-ethyl]-6-methyl-1H-indazol-4-yloxy} beta-D-glucopyranoside; sodium glucose transporter inhibitor; antidiabetic agent; Syndrome X, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, hypertension, ischemia, stroke, heart disease , and cataracts |
| 03/31/2009 | US7511020 2-[3-(4-Ethyl-benzyl)-3H-benzoimidazol-4-yloxy]- .squ. -D-glucoglucopyranoside; sodium glucose transporter inhibitor; antidiabetic agent; Syndrome X, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, and cataracts |
| 03/31/2009 | US7511019 Method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels in a human patient in need of treatment for coronary artery disease an effective amount of a recombinant fibroblast |
| 03/31/2009 | US7511017 Inhibiting apoptosis associated with HIV infection; immunoglobulin constant domain heterologous polypeptide; isolated nucleic acid encoding a human polypeptide, tumor necrosis factor receptor-5 |
| 03/31/2009 | US7511010 Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting Langerhans' cell migration |
| 03/31/2009 | US7510855 Comprises nucleotide sequences coding protein of urogenital system for identifying moduators for treatment of cell proliferative and metastatic disorders |
| 03/31/2009 | US7510853 Exhibiting similarity to cytokine; isolated or recombinant polynucleotide encoding antigenic polypeptide of sequence 2 |
| 03/31/2009 | US7510843 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 03/31/2009 | US7510830 Cancer treatment by combination therapy |
| 03/31/2009 | US7510828 Therapy, prevention of viral infections; obtaining viron sample; incubation, monitoring, calibration: using antithrombin agent |
| 03/31/2009 | US7510826 Process for the depletion or removal of endotoxins |
| 03/31/2009 | US7510825 Detecting perturbations and alterations of the normal organization of the cell plasma membrane (PNOM)-cells within a population of cells using a "perturbed membrane-binding compound" (PMBC) of given formula; e.g. monitoring aggressiveness of a tumor |
| 03/31/2009 | US7510733 Epimerdinoside a oral pharmaceutics containing the same and preparatory and determination methods |
| 03/31/2009 | US7510731 Water-soluble stabilized self-assembled polyelectrolytes |
| 03/31/2009 | US7510727 Unit dose sustained-release oral dosage form of melt extruded particles of specified particle size comprising a drug such as an opiod, one or more retardants, and an optional water insoluble binder |
| 03/31/2009 | US7510726 Methods and compositions for deterring abuse of opioid containing dosage forms |
| 03/31/2009 | US7510721 Multi-purpose acid compositions |
| 03/31/2009 | US7510710 Etomoxir and a 2-deoxy-D-glucose compound; antiinflammatory, antiproliferative, anticarcinogenic and wound healing agents; drug resistant cancers |
| 03/31/2009 | US7510708 Disruption of the REG pathway |
| 03/31/2009 | US7510706 Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity |
| 03/31/2009 | US7510704 4-hydroxy-3-methoxybenzyl alcohol and carrier; inhibitor of metabolism of selected corynebacteria; deodorants |
| 03/31/2009 | US7510702 Condensation aerosol for delivery of a drug selected from the group consisting of indomethacin, ketoprofen, celcoxib, rofecoxib, meclofenamic acid, fenoprofen, diflunisal, tolfenamic acid, naproxen, ibuprofen, flurbiprofen and nabumetone |
| 03/31/2009 | US7510567 Spinal implants, insertion instruments, and methods of use |
| 03/31/2009 | CA2506298C Conjugated fatty acid based emulsion and methods for preparing and using same |
| 03/31/2009 | CA2466654C Compositions comprising chitosan in the form of nano-sized fibres |
| 03/31/2009 | CA2448602C Pyrimidine, triazine and pyrazine derivatives as glutamate receptors |
| 03/31/2009 | CA2441313C New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| 03/31/2009 | CA2417897C Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| 03/31/2009 | CA2396734C Extraction of flavonoids |
| 03/31/2009 | CA2389749C Stable salts of novel derivatives of 3,3-diphenylpropylamines |
| 03/31/2009 | CA2366256C Tropane analogs and methods for inhibition of monoamine transport |
| 03/31/2009 | CA2356959C Water-insoluble drug delivery system |
| 03/31/2009 | CA2349268C A process for the preparation of suspensions of drug particles for inhalation delivery |
| 03/31/2009 | CA2339792C Opthalmic solution with tetracycline for topical treatment of dry eye disease |
| 03/31/2009 | CA2337175C Treatment of restenosis |
| 03/31/2009 | CA2328368C Anti-inflammatory agents |
| 03/31/2009 | CA2317582C A drug dosage form based on the teorell-meyer gradient |
| 03/31/2009 | CA2307285C Agent for prophylaxis and treatment of glaucoma |
| 03/31/2009 | CA2292549C Use of colchinol derivatives as vascular damaging agents |
| 03/31/2009 | CA2226894C 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
| 03/31/2009 | CA2193627C Subcutaneous implant |
| 03/31/2009 | CA2193597C Otic microbial combinations |
| 03/28/2009 | CA2640655A1 Anaplastic lymphoma kinase (alk) as oncoantigen for lymphoma vaccination |
| 03/26/2009 | WO2009039461A2 N-substituted piperidine derivatives as serotonin receptor agents |
| 03/26/2009 | WO2009039460A2 Co-administration of pimavanserin with other agents |
| 03/26/2009 | WO2009039442A1 Nfia in glial fate determination, glioma therapy and astrocytoma treatment |
| 03/26/2009 | WO2009039420A1 Methods and compositions for treating neuronal death mediated ocular diseases |
| 03/26/2009 | WO2009039397A2 Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer |
| 03/26/2009 | WO2009039388A2 Compositions and methods for detecting and treating ophthalmic disorders |
| 03/26/2009 | WO2009039387A1 Pyrazolo[5, 1-c] [1,2,4] triazines, methods for preparation and use thereof |
| 03/26/2009 | WO2009039362A2 Chiral synthesis of diazepinoquinolines |
| 03/26/2009 | WO2009039361A2 Process for the preparation of (s)-2-(3-tert-butylureido)-3,3-dimethylbutanoic acid |
| 03/26/2009 | WO2009039356A1 Treatment methods with brimonidine |
| 03/26/2009 | WO2009039328A1 Pyridyl sulfonamides as modulators of ion channels |
| 03/26/2009 | WO2009039324A1 Soluble dosage forms containing cephem derivatives suitable for parenteral administration |
| 03/26/2009 | WO2009039323A1 Prolyl hydroxylase inhibitors |
| 03/26/2009 | WO2009039322A1 Prolyl hydroxylase inhibitors |
| 03/26/2009 | WO2009039321A1 Prolyl hydroxylase inhibitors |
| 03/26/2009 | WO2009039313A1 Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors |
| 03/26/2009 | WO2009039266A1 Methods of increasing sarcosine levels for treating schizophrenia |
| 03/26/2009 | WO2009039262A2 Steroid containing ophthalmic drug delivery systems |
| 03/26/2009 | WO2009039246A2 Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection |
| 03/26/2009 | WO2009039226A1 Lyophilized pharmaceutical compositions |
| 03/26/2009 | WO2009039218A2 Compositions and methods for treating inflammation and inflammation-related disorders by plectranthus amboinicus extracts |
| 03/26/2009 | WO2009039199A2 Compositions comprising stat5 sirna and methods of use thereof |
| 03/26/2009 | WO2009039195A1 Resveratrol-containing compositions for modulating gene product concentration or activity |
| 03/26/2009 | WO2009039189A2 Compositions comprising stat3 sirna and methods of use thereof |
| 03/26/2009 | WO2009039177A1 6, 11-bicycloides: bridged biaryl macrolide derivatives |
| 03/26/2009 | WO2009039157A2 Orlistat pharmaceutical formulations |
| 03/26/2009 | WO2009039146A1 Modulation of growth hormone, dhea, and cortisol with positive modulators of ampa type glutamate receptors |
| 03/26/2009 | WO2009039140A1 Pyridopyrimidine derivatives as pi3 kinase inhibitors |
| 03/26/2009 | WO2009039135A1 N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors |
| 03/26/2009 | WO2009039134A1 Anti-infective pyrimidines and uses thereof |
| 03/26/2009 | WO2009039127A1 Uracil or thymine derivative for treating hepatitis c |
| 03/26/2009 | WO2009039102A1 Inhibitors of copn (cpn) for the treatment of bacterial infections |